|
1
|
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
|
J Clin Oncol
|
2009
|
2.54
|
|
2
|
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
|
Gastroenterology
|
2012
|
1.58
|
|
3
|
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.
|
Cancer Prev Res (Phila)
|
2011
|
1.57
|
|
4
|
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
|
Gynecol Oncol
|
2011
|
0.93
|
|
5
|
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
|
Cancer Prev Res (Phila)
|
2011
|
0.89
|
|
6
|
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
|
J Thorac Oncol
|
2010
|
0.87
|
|
7
|
Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222.
|
Cancer Manag Res
|
2009
|
0.76
|
|
8
|
Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
|
J Clin Pharmacol
|
2013
|
0.75
|
|
9
|
Randomized phase II trial of sulindac for lung cancer chemoprevention.
|
Lung Cancer
|
2012
|
0.75
|